Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer

Abstract

These findings highlight the adaptive dynamic regulation of PD-L1 in response to BCG immunotherapy and suggest that combination of BCG immunotherapy with PD-L1 blockade may be an effective antitumor strategy for improving treatment outcomes of BCa.